683 Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

683 Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-78,431	Closed	-$301K	–	137
2023 Q4	$301K	Buy	+78,431	New	+$233K	0.02%	117
2023 Q2	–	Sell	-31,246	Closed	-$127K	–	168
2023 Q1	$127K	Hold	31,246	–	–	0.01%	219
2022 Q4	$169K	Buy	+31,246	New	+$210K	0.01%	207

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

683 Capital Management's ABOS Position: Q1 2024 in Review

683 Capital Management sold out of Acumen Pharmaceuticals (ABOS) in Q1 2024, closing a stake of 78,431 shares — an estimated $301K sold.

683 Capital Management first reported a position in ABOS in Q4 2022 and held it in 3 quarters. The position peaked at $301K in Q4 2023. 80 funds tracked by Wall St. Rank hold ABOS as of Q1 2024.

683 Capital Management reported no remaining Acumen Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
683 Capital Management sold 78,431 Acumen Pharmaceuticals shares in Q1 2024, an estimated $301K.
683 Capital Management first reported a position in Acumen Pharmaceuticals in Q4 2022 and held it in 3 quarters.
683 Capital Management's Acumen Pharmaceuticals position peaked at $301K in Q4 2023.
80 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.